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Abstract Mild to moderate hyperhomocysteinemia has
been identified as a strong predictor of cardiovascular
disease, independent from classical atherothrombotic risk
factors. In the last decade, a number of large intervention
trials using B vitamins have been performed and have
shown no benefit of homocysteine-lowering therapy in
high-risk patients. In addition, Mendelian randomization
studies failed to convincingly demonstrate that a genetic
polymorphism commonly associated with higher homocys-
teine levels (methylenetetrahydrofolate reductase 677 C>T)
is a risk factor for cardiovascular disease. Together, these
findings have cast doubt on the role of homocysteine in
cardiovascular disease pathogenesis, and the homocysteine
hypothesis has turned into a homocysteine controversy. In
this review, we attempt to find solutions to this controversy.
First, we explain that the Mendelian randomization analyses
have limitations that preclude final conclusions. Second,
several characteristics ofinterventiontrialslimitinterpretation
andgeneralizabilityoftheirresults.Finally,thepossibilitythat
homocysteine lowering is in itself beneficial but is offset
by adverse side effects of B vitamins on atherosclerosis
deserves serious attention. As we explain, such side effects
may relate to direct adverse effects of the B-vitamin
regimen (in particular, the use of high-dose folic acid) or
to proinflammatory and proproliferative effects of B
vitamins on advanced atherosclerotic lesions.
Introduction
Mild hyperhomocysteinemia has been firmly established as
an independent predictor of cardiovascular disease (CVD).
A meta-analysis of studies published before 2002 conclud-
ed that a 3-μmol/l increase in fasting plasma homocysteine
is associated with an 11% increase in the incidence of
ischemic heart disease and a 19% increase in the incidence
of stroke (Homocysteine Studies Collaboration 2002;
Hansson 2005). More recent studies confirmed that homo-
cysteine is a strong, independent CVD predictor (de Ruijter
et al. 2009). The resulting homocysteine hypothesis states
that mild to moderate hyperhomocysteinemia is a causal
contributor (i.e., a risk factor) to the occurrence of CVD.
Not all disease predictors are risk factors in the strict
definition. A variable may predict disease without being
causally related to the disease. The common term for such a
predictor is biomarker (alternatively, the term risk marker or
risk indicator is used). A biomarker commonly represents
an early stage of the disease. Interventions aimed at
optimizing a biomarker may or may not be associated with
reduced disease incidence depending on whether the
treatment has an effect on a causal mechanism that
underlies both the appearance of the biomarker as well as
the occurrence of disease. Treatment that reduces the
biomarker without affecting disease incidence is useless.
Recent outcomes of large intervention trials have raised
suspicion that mild hyperhomocysteinemia is not a causal
risk factor but is, in fact, a predictor of CVD by virtue of a
role as biomarker, treatment of which does not reduce
clinical disease. A detailed analysis of the intervention
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DOI 10.1007/s10545-010-9151-1studies is presented elsewhere in this issue. In essence, the
collective evidence shows that treating mild hyperhomo-
cysteinemia (mean baseline homocysteine usually between
10 and 14 μmol/l) with B vitamins (folic acid, vitamin B12,
and vitamin B6, usually in combination) for a mean period
ranging from 2 to 7 years does not reduce the incidence of
clinical CVD endpoints.
Additional doubt for a causal role of homocysteine in
CVD has been raised in Mendelian randomization analyses.
Mendelian randomization is based on the principle that
genes are randomly allocated during meiosis, thus creating
a “trial of nature” (Davey Smith and Ebrahim 2003). If a
gene mutation is responsible for higher plasma homocys-
teine levels, random allocation of this gene during
conception essentially creates a randomized trial of low
versus high homocysteine from birth onward. The C > T
polymorphism in the methylenetetrahydrofolate reductase
(MTHFR) enzyme is such an example. Although initial
Mendelian randomization analyses supported the homocys-
teine hypothesis (Hansson 2005; Klerk et al. 2002), recent
similar analyses found no consistent effect of the Tallele on
CVD (Clarke 2009; Lewis et al. 2005).
Mendelian randomization studies in combination with
negative intervention trials have transformed the homocys-
teine hypothesis into a homocysteine paradox. We argue
that abandoning the hypothesis is premature. To make our
point, we address limitations of Mendelian randomization
and discuss limitations of intervention studies. In addition,
we discuss possible dual effects of B-vitamin supplemen-
tation on atherosclerosis, with intrinsic beneficial effects of
homocysteine lowering being offset by detrimental effects
of synthetic folic acid and/or stimulation of components of
atherosclerosis by B vitamins.
Limitations of Mendelian randomization
The principle of Mendelian randomization is illustrated in
Fig. 1 (Davey Smith and Ebrahim 2003). Although often
considered to provide the most objective type of epidemio-
logical evidence, the validity of a Mendelian randomization
analysis is critically dependent on a number of assumptions
(Sheehan et al. 2008), which we discuss below in the context
of the homocysteine hypothesis.
– The gene variant should have no relation with any of
the confounders.
Whether this assumption is met in the example of
MTHFR 677 C>T and the homocysteine hypothesis is
unknown. Certainly, full understanding of the factors
that may confound the association between homocys-
teine and CVD is essential. Given our limited ability to
explain population variance of plasma homocysteine
levels, we cannot safely exclude the possibility that the
MTHFR 677 C>T polymorphism is not related to any
confounder.
– The gene variant has a direct, consistent, and quanti-
fiable association with the risk factor.
This assumption is only partly met in the example of
MTHFR 677 C>Tand plasma homocysteine levels. For
example, the association is modified by systemic folate
status, measurements of which (e.g., serum folate)
notably have limited reliability.
– The gene variant has no direct effect on the disease, or
no effect other than that mediated via the risk factor of
interest.
Whether this assumption is valid for homocysteine
is uncertain. The MTHFR enzyme has a key role in
what is referred to as the metabolic switch in folate
metabolism. The 677 T allele is probably associated
with an increased flux of folate through the DNA-RNA
biosynthesis cycle. This is reflected, for example, by
increased concentrations of non-methyl-reduced folates
in erythrocytes of MTHFR 677 TT individuals
(Smulders et al. 2007). This preferential flux of folate
through the DNA-RNA biosynthesis cycle has been
suggested to play a role in the association between the
MTHFR 677 C>T polymorphism and various other
disease, in particular, cancer (Kim 2009). Whether
altered folate partitioning at the level of MTHFR also
directly (i.e., independently of homocysteine) affects
CVD development is unknown but cannot be excluded.
– The risk factor must itself be the cause of disease, not
an indirect reflection of a related causal factor.
Gene (i.e. MTHFR) Risk factor (i.e. homocysteine) Disease (i.e. CVD)
Confounders
Fig. 1 Principle of Mendelian randomization as applied to hyper-
homocysteinemia. This is the ideal model of Mendelian randomiza-
tion. Essential for the validity of the model is the absence of arrows
between the gene and (known or unknown) confounders, as well as
the absence of an arrow (i.e., a direct association not dependent on the
risk factor) between the gene and the disease. MTHFR methylenete-
trahydrofolate reductase, CVD cardiovascular disease
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understated. Ever since plasma homocysteine was iden-
tified as a risk factor for CVD, there has been a lack of
knowledge as to whether plasma homocysteine itself is
detrimental. Alternatively, raised plasma homocysteine
may represent changes in intracellular 1-carbon metabo-
lism that do not respond similarly to B-vitamin treatment,
asdoesplasmahomocysteine.Howintracellular1-carbon
metabolites relate to plasma homocysteine is, however,
unclear. Limited data suggest that, for example, plasma
homocysteinerelatestointracellular concentrationsofthe
transmethylation inhibitor S-adenosylhomocysteine
(Ado-Hcy) (Yi et al. 2000), but whether B vitamins
decrease intracellular Ado-Hcy levels is unknown.
Clearly, if homocysteine indirectly (and perhaps even
weakly) represents some epiphenomenon of an intracel-
lular disturbance in 1-carbon metabolism that causes
CVD, the Mendelian randomization study for the
MTHFR 677 C>T genotype loses significance.
A few additional limitations of Mendelian randomization
should be mentioned. These limitations include linkage
disequilibrium of the studied gene with other genes, genetic
heterogeneity, pleiotropy, and population stratification.
Finally, an important interpretative limitation is a phenom-
enon referred to as canalization, which describes the ability
of an organism to developmental compensation/adaptation
for a disruptive genetic condition.
In conclusion, many, if not all, of the assumptions
critical to the validity of Mendelian randomization experi-
ments are either absent or subject to doubt, and Mendelian
randomization has intrinsic limitations. The Mendelian
randomization study outcomes, therefore, are not suitable
to reject the homocysteine hypothesis.
Power of the intervention studies
The statistical power of an epidemiological study is defined
as the probability of identifying a truly existing outcome,
commonly a difference between (intervention) groups.
Usually, statistical power is interpreted solely in the context
of study size. This approach to statistical power carries with
it a few implicit assumptions, which impact on the actual
ability to observe anticipated effects—for example, of
homocysteine-lowering treatment.
Study duration
The estimated effect size of the intervention studies is
commonly based on observational epidemiology. Observa-
tional findings, however, almost always reflect exposure to
the treatment target (e.g., homocysteine) for a longer period
of time than the scheduled period of intervention and
follow-up. In other words, whereas the observational data
relating plasma homocysteine levels to CVD incidence are
based on exposure to hyperhomocysteinemia for a duration
that may easily exceed 10 years, most intervention trials
have a follow-up of <5 years.
In the field of CVD, a tradition has emerged to anticipate
relatively rapid effects of risk-reducing interventions.
Cholesterol lowering by statins, for example, has generated
positive results after follow-up durations of ≤2 years. Trials
of antihypertensive therapy have shown even more rapid
effects. The question now is whether it is reasonable to
expect a similarly rapid effect on CVD from any other
intervention. The answer is no.
The development of an atherosclerotic plaque is a slow
process, commonly taking 30–40 years from initial develop-
ment to a clinical event. If homocysteine were a true causal
contributor to this process, the time span required to show a
beneficial intervention effect of lowering homocysteine could
intuitively take much longer than the relatively few years of
follow-up characterizing the B-vitamin intervention trials.
Again, the statin and antihypertensive trials may have put us
on a wrong track of expectation. The speed of onset of
favorable effects of statins surprised researchers in the field
and remains incompletely understood. Conversely, the rapid
onset of a favorable effect of antihypertensive therapy was to
be expected in the first place, because the mechanical
unloading of the heart and vessel wall has immediate anti-
ischemicandplaque-stabilizingeffects.Thereareexamplesof
CVDriskreducinginterventionsthatindeedtakemuchlonger
than a few years to turn out positive. The best example is
glucose lowering. After disappointing results of intensive
glucosecontroloncardiovascularendpoints,extendedfollow-
up of studies in both type 1 and type 2 diabetes mellitus now
suggests that such effects may not become apparent until
10–15 years of follow-up (The DCCT/EDIC Research
Group 2005;H o l m a ne ta l .2008).
Although it is plausible that the homocysteine-lowering
trials have been underpowered simply because the duration
of follow-up has been too short, this possibility is rarely
even considered. A meta-analysis of the effect of B
vitamins on stroke, however, did look at the difference in
outcome between studies with <36 months and >36 months
of follow-up. The result of this analysis was a full absence
of any effect in the short-term studies but a statistically
significant 29% reduction in the studies with at least
36 months of follow-up (Wang et al. 2007).
Severity of hyperhomocysteinemia
Although the association between plasma homocysteine
concentrations and CVD appears linear in epidemiological
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relatively severe degrees of hyperhomocysteinemia generates
benefit. The baseline level of homocysteine in the large
intervention studies was usually between 10 and 14 μmol/l,
which is hardly above age-adjusted average population
values. Patients with higher levels of hyperhomocysteinemia
(e.g., >20 μmol/l) were underrepresented in the studies,
precluding definite conclusions for this category of patients.
Contrast between intervention groups
The power of any intervention study is dependent no so
much on the effect size of the active treatment, but rather
on the contrast generated between the intervention
groups. In this respect, several intervention trials have
been compromised by B-vitamin food fortification
implemented just prior to or during the intervention
period. In addition, the use of multivitamins is so
widespread that up to 20% of patients included in the
large B-vitamin trials were actually using multivitamins
at the time of randomization.
The impact of contrast between the intervention groups
has not been sufficiently addressed. In the aforementioned
meta-analysis of stroke prevention by B vitamins, however,
there was a significant impact of both grain fortification and
the degree of homocysteine lowering on the probability of
finding a protective effect of B vitamins on stroke
incidence. Intervention effects were not observed in
fortified study populations or if the degree of homocysteine
lowering was <20% compared with baseline (Wang et al.
2007).
Inconclusion,althoughthecumulativeinterventionstudies
contain a large number of patients, the actual power to detect
an intervention effect may be compromised by a duration of
follow-up that is simply too short in relation to the time frame
of the development of atherosclerotic disease. In addition,
conclusions from intervention studies may not apply to
patientswithmoderatehyperhomocysteinemia—forexample,
exceeding 20 μmol/l—or to patients not exposed to multi-
vitamins or food fortification with B vitamins.
Dual effects of B vitamins on atherosclerosis
The interpretation of identical event-free survival rates in
clinical trials is intuitively interpreted as being compatible
with “no effect” of the active treatment compared with
placebo. The more correct phrasing would be, however, that
“no net effect” is observed. By this, we mean that the
apparent absence of an effect may in fact be the sum of
favorable and unfavorable effects, which balance out in the
clinical event rate.
It is conceivable that B-vitamin treatment has such dual
effects on atherosclerosis. The favorable effect would be
reduction of homocysteine levels. The unfavorable effects
may relate to several aspects of B-vitamin treatment. We
briefly discuss two such aspects: potential adverse effects of
unmetabolized folic acid, and stimulation of inflammation
(and possibly proliferation) in existing atherosclerotic
lesions.
Potential adverse effects of folic acid
Folic acid is a synthetic, oxidized provitamin used for food
supplementation and pharmacological formulations mainly
because it is cheap and stable during manufacturing,
storage, and food processing. Folic acid, however, does
not occur in normal human physiology and has no known
biological function of its own. It requires reduction to
tetrahydrofolate and subsequently needs 1-carbon substitu-
tion to commence its task as 1-carbon donor for methyla-
tion and DNA-RNA synthesis. During passage of small
amounts of folic acid through the gut cells and liver,
reduction and 1-carbon substitution is complete, and
5-methyltetrahydrofolate is by far the most predominant
form entering the systemic circulation. When the dose of
folic acid exceeds 200 μg, however, unmetabolized folic
acid appears in the systemic circulation (Kelly et al. 1997).
The potential adverse effects of circulating folic acid have
been understudied. It is possible, however, that folic acid
has adverse effects on normal transmembrane folate
transport and/or has direct detrimental intracellular effects.
Folate transport across epithelia and into systemic tissues
predominantly occurs via the reduced folate carrier, the
folate receptor family, and the recently discovered proton-
coupled folate transporter (Zhao et al. 2009). The role of
the proton-coupled folate transporter is unclear in tissues
other than the gut (Zhao et al. 2009). The reduced folate
carrier has almost exclusive affinity and transport capacity
for reduced folates. The folate receptors, however, can bind
different isoforms of folate. The potential problem is that
folic acid has an affinity for the folate receptor that is many
times stronger than that of reduced folates. This high
affinity may result in limited or delayed detachment of folic
acid from the receptor after cellular internalization of the
receptor–folate complex, which would essentially render
folate-receptor-mediated transport ineffective. This may, at
least theoretically, cause relative folate deprivation in cells
that are dependent on the receptor for folate supply.
Whether this problem occurs in reality is speculative. No
study, however, has addressed this issue. In addition,
knowledge of transmembrane folate transport mechanisms
in cells that are important for atherosclerosis, such as
endothelial cells, monocytes–macrophages, vascular
smooth muscle cells, etc., is incomplete, which adds to the
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affect transmembrane transport of 5-methyltetrahydrofolate.
Another issue is whether folic acid could have direct
adverse effects. Again, the literature has not thoroughly
addressed this possibility. A single report, however,
suggested that unmetabolized folic acid may adversely
affect natural-killer-cell function (Troen et al. 2006). On
a molecular level, folic acid may impair enzymes for
which reduced folates are natural substrates (Ross et al.
1984). Whether such mechanisms are relevant for clinical
diseases is unknown. However, indirect support is
emerging from epidemiological studies, such as a study
suggesting that folic acid supplements increase prostate
cancer risk, whereas folate status resulting from natural
folate intake is inversely related to this risk (Figueiredo
et al. 2009).
Adverse effects of folate on atherosclerosis
A final source of concern is that the beneficial effect of
homocysteine lowering is offset by folate supplementation
having detrimental effects on inflammation and proliferation
in atherosclerotic lesions. Atherosclerosis is not a process of
passive cholesterol accumulation in the arterial wall but,
rather, a disease in which many metabolically active and
proliferating cells play a role. Macrophages, for example, are
important in the development of atherosclerosis by incorpo-
rating and accumulating oxidized low-density-lipoprotein
cholesterol particles. Also, activated T cells play a role in
atherosclerosis (Hansson 2005). Examples of proliferative
processes essential in atherosclerosis include neoangiogene-
sis of microvessels and smooth muscle cell proliferation
(Hansson 2005; Sluimer and Daemen 2009). Given the role
of folate in transmethylation reactions and DNA/RNA
synthesis, B-vitamin cofactors of 1-carbon metabolic cycles
should be considered crucial fuel sources of all metabolically
active and proliferating cells, including those responsible for
inflammation and proliferation in atherosclerosis.
This hypothesis may implicate that the effects of homo-
cysteine lowering by B vitamins may be dependent upon
disease stage. In true primary prevention (i.e., absence of
atherosclerotic lesions in any more or less advanced stage of
development), the lower homocysteine might still have
beneficial effects. However, in patients with significant
atherosclerotic lesions already being present (i.e., the elderly)
the B vitamins may have detrimental effects, neutralizing the
benefit of homocysteine lowering. Whether the hypothesis of
disease-stage-dependent effects of B vitamins holds true, and
B vitaminsindeedhavethe potential toenhance inflammation
and proliferation in atherosclerotic lesions, has never been
specifically studied. There is, however, considerable indirect
support for this hypothesis from human and other animal cell
studies, which we discuss briefly below.
If high B-vitamin status protects against initial atheroscle-
rotic lesion development but enhances the disease process in
later stages, this could be reflected in epidemiological
findings. Indeed, population-based studies have suggested
thatwhereashighfolatestatusmayprotectyoungpeoplefrom
CVD, elderly people (in whom advanced atherosclerosis is
commonly present) actually benefit from relative folate
deprivation (Giles et al. 1998). In addition, one might expect
to see particular beneficial effects of antifolate treatment on
atherosclerosis-related clinical events. Accordingly, the anti-
folate methotrexate appears to have specific anti-CVD
properties in rheumatoid arthritis patients, its benefits
exceeding that of other anti-inflammatory agents that are
without specific antifolate properties (van Halm et al. 2006).
Whether methotrexate really can delay atherothrombotic
events is being evaluated in a large, randomized clinical
trial (Ridker 2009). It is at least remarkable that folate
supplementation trials are being performed by some, and
antifolate treatment by others, without anyone realizing that
the hypotheses underlying these trials are, at least partly,
mirror images.
Several animal studies have confirmed that B vitamins
indeed delay initial development of atherosclerosis (Dayal
and Lentz 2008; Carnicer et al. 2007), but putative
detrimental effects of folate on advanced lesions have never
been specifically addressed (Dayal and Lentz 2008). We are
undertaking such studies. As for the putative detrimental
effects of B vitamins on inflammatory and proliferating
cells, folate dependency has been observed for activated
macrophages (Xia et al. 2009; Antohe et al. 2005). Folate
has been shown to enter and stimulate activated macro-
phages (Xia et al. 2009), thereby skewing them to a more
proatherogenic phenotype. In addition, the fact that cells do
not proliferate in folate-deprived media is a well-known
phenomenon from in vitro studies. Again, however, no
previous study has specifically addressed the possibility of
B-vitamin-mediated enhancement of proliferative processes
taking place in atherosclerotic lesions.
Conclusions and implications
Recently, the outcome of Mendelian randomization studies
and large intervention trials of homocysteine lowering have
cast doubt on the role of B vitamins and homocysteine in
CVD. In our view, what the intervention trials have indeed
convincingly shown is that routine administration of high-
dose multi-B vitamins to patients with (a high risk of) CVD
has no net benefit and can thus not be recommended.
However, abandoning the field of research into the associa-
tions between B vitamins, homocysteine, and CVD would be
unwise. As outlined, the Mendelian randomization experi-
ments have limitations that preclude final conclusions. In
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the interpretation of their results. Finally, the possibility that
homocysteine lowering is beneficial but is offset by adverse
side effects of B-vitamin supplementation on atherosclerosis
deserves serious attention. As explained, these side effects
may relate to direct adverse effects of the B-vitamin regimen
(in particular, the use of high-dose folic acid), or to
proinflammatory and proproliferative effects of B vitamins
on advanced atherosclerotic lesions.
There are several implications to what we have discussed.
First, we need to increase our understanding of how
homocysteine damages the vascular system and what ways
of preventing such damage, other than high-dose B vitamins,
are possible. Second, we must study the potential adverse
effects of the various forms of (high-dose) B vitamins in cell
and animal experiments. Third, we should use epidemiolog-
icaldatatoexplore the hypothesisthata high B-vitaminstatus
mayindeedprevent the initialdevelopment ofatherosclerosis,
particularlyinyoungpeople.Interventiontrialsinsuchpeople
will be very hard to perform logistically, especially with hard
clinical endpoints. Finally, we must continue to perform
intervention trials addressing questions that have remained
unanswered in the trials performed so far. In particular, these
remaining questions relate to the type of intervention (e.g.,
natural folate versus folic acid), the duration of follow-up
(e.g., long-term studies or, at least, extended follow-up of
the existing studies), and the target population (e.g.,
separate studies in patients with more severe degree of
hyperhomocysteinemia). Abandoning the homocysteine
hypothesis now might well turn out to be a historical
mistake.
Awaiting the results of studies to come, what should
we do with our high-risk patient? Clearly, an evidence-
based recommendation is impossible. The evidence
collected so far allows for just a single conclusion:
high-dose B-vitamin therapy in all patients at high risk
of CVD does not reduce events after 5 years. In view
of what we have discussed, the following policy may
be considered:
– Do not screen for hyperhomocysteinemia routinely in
high-risk patients, but only if:
& An inborn error of 1-carbon metabolism is suspected
based on the clinical phenotype
& CVD occurs prematurely (i.e., <50 years, cutoff
depending on conventional risk-factor profile) in the
patient or his/her family
& B-vitamin depletion is suspected based on history or
comorbidity
– Do not treat mild hyperhomocysteinemia routinely, but
only if fasting levels exceed a certain threshold of, for
example, 20–25 μmol/l
– Upon decision to treat, do not use high-dose B-vitamin
preparations routinely, but start with a multivitamin
containing moderate amounts of folate, B12, and B6.
– Switch to high-dose B vitamins only if homocysteine
remains clearly elevated
– Keep an eye on the literature
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